Page 1209 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 1209

Index     1195


                      structure of, 162, 163f          Biological License Application (BLA), 17  Blood clotting factors, 610t,
                      toxicity of, 169–170             Biologics, for inflammation, 643          610–611, 611f
                      types of, 164t, 165–167          Biomagnification, 1006b            Blood concentration-time curve, 47, 47f
                      variceal hemorrhage treated with, 1114  Biotransformation, drug, 56–73  Blood:gas partition coefficient, 443t, 444,
                    b-selective agonists, 141t, 149, 149f  commensal gut microbiota in, 69–70    444f
                    b 1 -selective agonists, 99t, 141t, 149, 149f,   in drug disposition, 57, 57f  Blood glucose, self-monitoring of, 753
                            154t                         drug metabolism in               Blood pressure
                    b 2 -selective agonists, 154t, 362t    clinical relevance of, 64–72     angiotensin II on, 303
                      asthma treated with, 351             to toxic products, 64–65, 65f    female hormonal contraceptives effect
                      preparations available, 363t       in liver, 57–58                         on, 733
                      structure of, 149f                 liver P450 enzymes in, 59–61, 62t–63t  regulation of, 173–175
                    b 3 -selective agonists, 154t        necessity for, 56–57                 normal, 174f, 174–175
                    Betaxolol. See also b-receptor antagonist   phase II reactions in, 57, 57f, 63, 64f, 64t  postural baroreflex in, 175, 175f
                            drugs                        phase I reactions in                 renal response to decreased blood
                      description of, 164t, 166, 168, 170t  description of, 57, 57f              pressure in, 175
                      hypertension treated with, 183       microsomal mixed function oxidase   Blood schizonticides, 917, 918f
                    Bethanechol, 109, 109f, 118, 122t          system and, 58f, 58–59     B lymphocytes, 950
                    Bethanidine, 181                   Biperiden, 501t, 508t              Bond
                    Bevacizumab, 966t, 968, 991–992, 1065  Bipolar affective disorder       covalent, 3–4
                    Bexarotene, dermatologic, 1085       drugs for, 524–528                 drug–receptor, 3–4
                    Bezafibrate, 634                       antipsychotics, 519              electrostatic, 3–4
                    Bezold-Jarisch reflex, 287             carbamazepine, 528, 529t         hydrophobic, 3–4
                    Biased agonists, 141                   lamotrigine, 528, 529t         Bone marrow transplantation
                      at b receptors, 142b                 lithium, 524–528, 526, 529t      immune globulin, intravenous for, 1180t
                    BIBP3226, 318t. See also Neuropeptide Y   preparations available, 529t  immunosuppressive therapy for, 996
                            antagonists                    valproic acid, 528, 529t       Bone mineral homeostasis
                    Bicalutamide, 744, 972               history of, 524                    calcitonin in, 773, 774f
                    Biguanides, 759–760, 768t            nature of, 524                     calcium and phosphate in, 772, 773f
                    BIIE0246, 318t. See also Neuropeptide Y   pathophysiology of, 524       1,25-dihydroxyvitamin D in, 773, 774f
                            antagonists                Bipyridines, 219, 225t             Bone mineral homeostasis drugs, 772, 789t
                    Bile acid–binding resins, 636–637, 639t  Bipyridyl herbicides, 1013f, 1014  clinical pharmacology of, 782–789
                      drug interactions of, 1161t      Bisacodyl, 1099                        calcium levels in, abnormal serum
                      with ezetimibe, niacin, and reductase   Bismuth compounds, colloidal, 1100  hypercalcemia, 782–783
                            inhibitors, 639            Bismuth subcitrate potassium, 1096      hypocalcemia, 783–784
                      with fibric acid derivatives, 638  Bismuth subsalicylate, 1096          enteric oxaluria, 789
                      with HMG CoA reductase inhibitors,   Bisoprolol. See also b-receptor antagonist   mineral-regulating hormone uses in,
                            639                                drugs                             784–788
                      with niacin, 639                   heart failure treated with, 221, 222, 225t  chronic kidney disease, 785–786
                    Bile acid sequestrants               hypertension treated with, 183        hereditary vitamin D–resistant
                      diabetes mellitus treated with, 764, 769t  properties of, 164t             rickets, 788
                      dyslipidemia treated with, 639t  Bisphosphonates                         hyperparathyroidism, primary, 784
                    Bile acid therapy, for gallstones,   bone homeostasis affected by, 779f,   hypoparathyroidism, 784–785
                            1113–1114, 1116t, 1117t            779–781, 790t                   idiopathic hypercalciuria, 788
                    Bile salt–binding resins, 1100       bone metastases treated with, 789t    intestinal osteodystrophy, 786
                    Bimatoprost                          hypercalcemia treated with, 782, 789t  nephrotic syndrome, 788
                      glaucoma treated with, 337         osteoporosis treated with, 780b, 786, 789t  nutritional rickets, 788
                      ophthalmic, 1085                   Paget’s disease of bone treated with, 789  osteoporosis, 786–787, 787f
                    Binding sites, inert, 7            Bithionol, 939t, 940                    pseudovitamin D deficiency rickets,
                    Binge drinking, 401                Bitopertin, 515                           788
                    Bioaccumulation, 1006b             Bivalirudin, 617–618                    vitamin D deficiency/insufficiency,
                    Bioavailability, 47–48             Black cohosh, 1133t                       nutritional, 785
                      extent of absorption in, 47, 47f, 47t  Blackwater fever, 924             X-linked and autosomal dominant
                      first-pass elimination in, 47–48  Black widow spider bite, 1180t           hypophosphatemia, 787–788
                      rate of absorption in, 47f, 48   Bleach, household, 899                 Paget’s disease of bone, 788–789
                    Biologic agents, for psoriasis, 1079  Bleomycin, 962t, 965–966            phosphate levels in, abnormal serum
                      fumaric acid esters, 1079        Blepharospasm, 106                      hyperphosphatemia, 784
                      TNF inhibitors, 1079             Blind designs, 14                       hypophosphatemia, 784
                      ustekinumab, 1079                Blood–brain barrier, 368–369           presentation in, 782
   1204   1205   1206   1207   1208   1209   1210   1211   1212   1213   1214